Tags

Type your tag names separated by a space and hit enter

Anorectic state of obesity medications in the United States. Are leaner times ahead?
Expert Opin Pharmacother. 2020 Feb; 21(2):167-172.EO

Abstract

Introduction: Obesity is considered to be a chronic disease. Currently there are five prescription-only medications on the US market for the long-term management of obesity. However, these medications are underutilized by obese or overweight individuals seeking medical assistance for weight management.Areas covered: This special report provides an overview of the emerging obesity pharmacotherapies based on the data available from recruiting and active phase II/III trials from a registry of clinical trials. The authors also give their expert opinion and provide their future perspectives on the treatment of obesity based on what is known.Expert opinion: Despite obesity being a chronic condition affecting 40% of the US population, there is a low demand for obesity medications in the US market. Although the potential obesity medications that are currently being investigated in phase II/III clinical trials are promising, it is unclear whether the future pharmacotherapies will be enough to meet the health care need.

Authors+Show Affiliations

Department of Animal Sciences, School of Environmental and Biological Sciences, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA. Nutritional Sciences Graduate Program, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.Department of Animal Sciences, School of Environmental and Biological Sciences, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA. Nutritional Sciences Graduate Program, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA. New Jersey Institute for Food, Nutrition, and Health, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

31762335

Citation

Li, Xinyi, and Nicholas T. Bello. "Anorectic State of Obesity Medications in the United States. Are Leaner Times Ahead?" Expert Opinion On Pharmacotherapy, vol. 21, no. 2, 2020, pp. 167-172.
Li X, Bello NT. Anorectic state of obesity medications in the United States. Are leaner times ahead? Expert Opin Pharmacother. 2020;21(2):167-172.
Li, X., & Bello, N. T. (2020). Anorectic state of obesity medications in the United States. Are leaner times ahead? Expert Opinion On Pharmacotherapy, 21(2), 167-172. https://doi.org/10.1080/14656566.2019.1692815
Li X, Bello NT. Anorectic State of Obesity Medications in the United States. Are Leaner Times Ahead. Expert Opin Pharmacother. 2020;21(2):167-172. PubMed PMID: 31762335.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Anorectic state of obesity medications in the United States. Are leaner times ahead? AU - Li,Xinyi, AU - Bello,Nicholas T, Y1 - 2019/11/24/ PY - 2021/02/01/pmc-release PY - 2019/11/26/pubmed PY - 2020/3/11/medline PY - 2019/11/26/entrez KW - MEDI0382 KW - Orlistat KW - dapagliflozin KW - liraglutide KW - lorcaserin KW - naltrexone/bupropion KW - phentermine/topiramate KW - semaglutide KW - setmelanotide KW - tesofensine SP - 167 EP - 172 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 21 IS - 2 N2 - Introduction: Obesity is considered to be a chronic disease. Currently there are five prescription-only medications on the US market for the long-term management of obesity. However, these medications are underutilized by obese or overweight individuals seeking medical assistance for weight management.Areas covered: This special report provides an overview of the emerging obesity pharmacotherapies based on the data available from recruiting and active phase II/III trials from a registry of clinical trials. The authors also give their expert opinion and provide their future perspectives on the treatment of obesity based on what is known.Expert opinion: Despite obesity being a chronic condition affecting 40% of the US population, there is a low demand for obesity medications in the US market. Although the potential obesity medications that are currently being investigated in phase II/III clinical trials are promising, it is unclear whether the future pharmacotherapies will be enough to meet the health care need. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/31762335/Anorectic_state_of_obesity_medications_in_the_United_States._Are_leaner_times_ahead L2 - http://www.tandfonline.com/doi/full/10.1080/14656566.2019.1692815 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.